---
document_datetime: 2025-12-02 05:20:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lopinavir-ritonavir-viatris.html
document_name: lopinavir-ritonavir-viatris.html
version: success
processing_time: 0.1401388
conversion_datetime: 2025-12-25 09:49:16.303074
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

[RSS](/en/individual-human-medicine.xml/67053)

##### Authorised

This medicine is authorised for use in the European Union

lopinavir / ritonavir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78988)
- [More information on Lopinavir/Ritonavir Mylan](#more-information-on-lopinavirritonavir-mylan-1524)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Lopinavir/Ritonavir Viatris is used in combination with other medicines to treat patients over two years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).

Lopinavir/Ritonavir Viatris contains the active substances lopinavir and ritonavir.

Lopinavir/Ritonavir Viatris is a 'generic medicine'. This means that it contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Lopinavir/Ritonavir Viatris is Kaletra. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Lopinavir/Ritonavir Viatris used?

Lopinavir/Ritonavir Viatris can only be obtained with a prescription and treatment should be started by a doctor who is experienced in managing HIV infection. It is available as tablets to be taken by mouth.

For more information about using Lopinavir/Ritonavir Viatris, see the package leaflet or contact your doctor or pharmacist.

## How does Lopinavir/Ritonavir Viatris work?

The active substances in this medicine, lopinavir and ritonavir, are protease inhibitors: they block an enzyme called protease that is involved in the replication of HIV. When the enzyme is blocked, the virus does not replicate normally, slowing down the spread of infection. In Lopinavir/Ritonavir Viatris, lopinavir provides the activity and ritonavir is used as a 'booster' that slows down the rate at which lopinavir is broken down by the liver. This increases the levels of lopinavir in the blood, allowing a lower dose of lopinavir to be used for the same antiviral effect.

Lopinavir/Ritonavir Viatris, taken with other HIV medicines, reduces HIV in the blood and keeps the virus at a low level. It does not cure HIV infection, but it can hold off damage to the immune system and avoid the development of infections and diseases associated with AIDS.

## How has Lopinavir/Ritonavir Viatris been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Kaletra, and do not need to be repeated for Lopinavir/Ritonavir Viatris.

As for every medicine, the company provided studies on the quality of Lopinavir/Ritonavir Viatris. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Lopinavir/Ritonavir Viatris?

Because Lopinavir/Ritonavir Viatris is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Lopinavir/Ritonavir Viatris authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Lopinavir/Ritonavir Viatris has been shown to have comparable quality and to be bioequivalent to Kaletra. Therefore, the Agency's view was that, as for Kaletra, the benefit outweighs the identified risk and it can be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Lopinavir/Ritonavir Viatris?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lopinavir/Ritonavir Viatris have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Kaletra also apply to Lopinavir/Ritonavir Viatris where appropriate.

As for all medicines, data on the use of Lopinavir/Ritonavir Viatris are continuously monitored. Suspected side effects reported with Lopinavir/Ritonavir Viatris are carefully evaluated and any necessary action taken to protect patients.

## Other information about Lopinavir/Ritonavir Viatris

Lopinavir/Ritonavir Mylan received a marketing authorisation valid throughout the EU on 14 January 2016.

The name of the medicine was changed to Lopinavir/Ritonavir Viatris on 13 June 2024.

Lopinavir/Ritonavir Viatris : EPAR - Medicine overview

Reference Number: EMA/284756/2024

English (EN) (139.75 KB - PDF)

**First published:** 09/02/2016

**Last updated:** 07/01/2025

[View](/en/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-304)

български (BG) (158.66 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/bg/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_bg.pdf)

español (ES) (133.76 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/es/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_es.pdf)

čeština (CS) (155.06 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/cs/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_cs.pdf)

dansk (DA) (132.1 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/da/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_da.pdf)

Deutsch (DE) (136.99 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/de/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_de.pdf)

eesti keel (ET) (130.26 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/et/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_et.pdf)

ελληνικά (EL) (157.43 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/el/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_el.pdf)

français (FR) (135.13 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/fr/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_fr.pdf)

hrvatski (HR) (152.08 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/hr/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_hr.pdf)

italiano (IT) (132.19 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/it/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (162.79 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/lv/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (154.42 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/lt/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_lt.pdf)

magyar (HU) (154.2 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/hu/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_hu.pdf)

Malti (MT) (155.9 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/mt/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_mt.pdf)

Nederlands (NL) (133.68 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/nl/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_nl.pdf)

polski (PL) (159.04 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/pl/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_pl.pdf)

português (PT) (134.62 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/pt/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_pt.pdf)

română (RO) (153.27 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/ro/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_ro.pdf)

slovenčina (SK) (154.37 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/sk/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_sk.pdf)

slovenščina (SL) (151.57 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/sl/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_sl.pdf)

Suomi (FI) (130.75 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/fi/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_fi.pdf)

svenska (SV) (130.65 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

07/01/2025

[View](/sv/documents/overview/lopinavir-ritonavir-viatris-epar-medicine-overview_sv.pdf)

Lopinavir/Ritonavir Mylan : EPAR - Risk-management-plan summary

English (EN) (147.89 KB - PDF)

**First published:** 09/02/2016

**Last updated:** 04/06/2021

[View](/en/documents/rmp-summary/lopinavirritonavir-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Lopinavir/Ritonavir Viatris : EPAR - Product Information

English (EN) (632.34 KB - PDF)

**First published:** 09/02/2016

**Last updated:** 08/09/2025

[View](/en/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-727)

български (BG) (836.09 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/bg/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_bg.pdf)

español (ES) (655.6 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/es/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_es.pdf)

čeština (CS) (752.49 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/cs/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_cs.pdf)

dansk (DA) (792.33 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/da/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_da.pdf)

Deutsch (DE) (687.05 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/de/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_de.pdf)

eesti keel (ET) (548.77 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/et/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (705.8 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/el/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_el.pdf)

français (FR) (841.08 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/fr/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (901.02 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/hr/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_hr.pdf)

íslenska (IS) (840.05 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/is/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_is.pdf)

italiano (IT) (999.41 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/it/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (779.1 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/lv/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (941.85 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/lt/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_lt.pdf)

magyar (HU) (952.34 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/hu/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_hu.pdf)

Malti (MT) (918.63 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/mt/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (945.58 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/nl/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_nl.pdf)

norsk (NO) (534.99 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/no/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_no.pdf)

polski (PL) (750.94 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/pl/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_pl.pdf)

português (PT) (562.72 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/pt/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_pt.pdf)

română (RO) (1.01 MB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/ro/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (941.19 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/sk/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_sk.pdf)

Suomi (FI) (837.05 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/fi/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_fi.pdf)

svenska (SV) (840.05 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

08/09/2025

[View](/sv/documents/product-information/lopinavir-ritonavir-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000291122 05/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lopinavir/Ritonavir Viatris : EPAR - All Authorised presentations

English (EN) (9.36 KB - PDF)

**First published:** 09/02/2016

**Last updated:** 22/07/2024

[View](/en/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-731)

български (BG) (47.88 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/bg/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_bg.pdf)

español (ES) (11.42 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/es/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (47.26 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/cs/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.65 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/da/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (11.75 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/de/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (84.3 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/et/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (32.37 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/el/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_el.pdf)

français (FR) (13.25 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/fr/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (29.79 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/hr/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (12.65 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/is/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (12.8 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/it/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (86.11 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/lv/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (86.94 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/lt/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.79 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/hu/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (33.14 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/mt/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (10.62 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/nl/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (8.71 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/no/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_no.pdf)

polski (PL) (33.58 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/pl/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_pl.pdf)

português (PT) (8.92 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/pt/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_pt.pdf)

română (RO) (44.23 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/ro/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (22.7 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/sk/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (23.58 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/sl/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.8 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/fi/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (8.61 KB - PDF)

**First published:**

09/02/2016

**Last updated:**

22/07/2024

[View](/sv/documents/all-authorised-presentations/lopinavir-ritonavir-viatris-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan) Active substance

- lopinavir
- ritonavir

International non-proprietary name (INN) or common name

- lopinavir
- ritonavir

Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AR10

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.

The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

## Authorisation details

EMA product number EMEA/H/C/004025

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Mulhuddart Dublin 15 Ireland

Opinion adopted 19/11/2015 Marketing authorisation issued 14/01/2016 Revision 22

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lopinavir/Ritonavir Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (132.9 KB - PDF)

**First published:** 22/07/2024

**Last updated:** 08/09/2025

[View](/en/documents/procedural-steps-after/lopinavir-ritonavir-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Lopinavir/Ritonavir Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (133.77 KB - PDF)

**First published:** 08/07/2016

**Last updated:** 30/01/2024

[View](/en/documents/procedural-steps-after/lopinavir-ritonavir-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Lopinavir/Ritonavir Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/828552/2015

English (EN) (492.44 KB - PDF)

**First published:** 09/02/2016

**Last updated:** 09/02/2016

[View](/en/documents/assessment-report/lopinavirritonavir-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Lopinavir / Ritonavir Mylan

Adopted

Reference Number: EMA/CHMP/772058/2015

English (EN) (69.09 KB - PDF)

**First published:** 20/11/2015

**Last updated:** 20/11/2015

[View](/en/documents/smop-initial/chmp-summary-opinion-lopinavir-ritonavir-mylan_en.pdf)

#### News on Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 November 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-november-2015) 20/11/2015

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Lopinavir/Ritonavir Viatris : EPAR - Product information - tracked changes

English (EN) (225.27 KB - DOCX)

**First published:** 08/09/2025

[View](/en/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-894)

български (BG) (268.82 KB - DOCX)

**First published:**

08/09/2025

[View](/bg/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_bg.docx)

español (ES) (249.77 KB - DOCX)

**First published:**

08/09/2025

[View](/es/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_es.docx)

čeština (CS) (221.17 KB - DOCX)

**First published:**

08/09/2025

[View](/cs/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (202.18 KB - DOCX)

**First published:**

08/09/2025

[View](/da/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (227.27 KB - DOCX)

**First published:**

08/09/2025

[View](/de/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (231.98 KB - DOCX)

**First published:**

08/09/2025

[View](/et/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (264.97 KB - DOCX)

**First published:**

08/09/2025

[View](/el/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_el.docx)

français (FR) (228.02 KB - DOCX)

**First published:**

08/09/2025

[View](/fr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (216.79 KB - DOCX)

**First published:**

08/09/2025

[View](/hr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (203.53 KB - DOCX)

**First published:**

08/09/2025

[View](/is/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_is.docx)

italiano (IT) (280.89 KB - DOCX)

**First published:**

08/09/2025

[View](/it/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (237.89 KB - DOCX)

**First published:**

08/09/2025

[View](/lv/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (229.7 KB - DOCX)

**First published:**

08/09/2025

[View](/lt/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (235.6 KB - DOCX)

**First published:**

08/09/2025

[View](/hu/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (235.86 KB - DOCX)

**First published:**

08/09/2025

[View](/mt/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (232.35 KB - DOCX)

**First published:**

08/09/2025

[View](/nl/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (232.1 KB - DOCX)

**First published:**

08/09/2025

[View](/no/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_no.docx)

polski (PL) (250 KB - DOCX)

**First published:**

08/09/2025

[View](/pl/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_pl.docx)

português (PT) (218.21 KB - DOCX)

**First published:**

08/09/2025

[View](/pt/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_pt.docx)

română (RO) (221.76 KB - DOCX)

**First published:**

08/09/2025

[View](/ro/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (235.1 KB - DOCX)

**First published:**

08/09/2025

[View](/sk/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (338.84 KB - DOCX)

**First published:**

08/09/2025

[View](/sl/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (234.25 KB - DOCX)

**First published:**

08/09/2025

[View](/fi/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (219.79 KB - DOCX)

**First published:**

08/09/2025

[View](/sv/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_sv.docx)

#### More information on Lopinavir/Ritonavir Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 08/09/2025

## Share this page

[Back to top](#main-content)